Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510630, China
Location status: Recruiting
Recruiting
NCT Number: NCT07160946
Risk Assessment for HBV-Related Liver Cancer
Liver cancer is a severe disease worldwide. The incidence and mortality rates of liver cancer in China is the highest in the world. This project aims to perform a prospective, multi-center, large sample cohort study for HBV related high-risk individuals. Based on multimodal data fusion and AI technique, stratified management and follow-up system are conducted for HBV-related high-risk populations of liver cancer, in order to improve the early diagnosis rate of liver cancer.
Recruiting
Interested in participating?
Request InfoKey information
Conditions
Age range
30 year–75 year
Sex eligibility
All sexes
Study type
Observational
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
must meet (a) and any one of (b) to (g).
- (a).Positive for Hepatitis B surface antigen; (b).Ultrasound/CT/MR indicates liver cirrhosis; (c). Type II diabetes; (d). Has family history of liver cirrhosis/ liver cancer; (e). Long term alcohol consumption history (>5 years), equivalent to alcohol consumption of ≥ 40g/d for males and ≥ 20g/d for females; (f). Liver histology Metavir fibrosis score F3 or above; (g). Fibroscan value (LSM) ≥ 8.0kPa.
Exclusion criteria
- (a).Diagnosed with malignant tumors; (b). Post liver transplantation; (c). Infected with HIV; (d). Expected survival time<1 year; (e). With marked organ dysfunctions(heart, brain, kidney, lung, endocrine system, blood, etc.) or psychiatric patients.
Treatment and study plan
AI folow-up system
OtherIn AI follow-up group, patients will be followed up by an AI system.
Primary outcomes
-
Number and specific time of participants progressing to liver cancer
Time frame: 5 years
Number and specific time of participants progressing to liver cancer
Secondary outcomes
-
Survival time
Time frame: 5 years
Participants' survival time after being diagnosed with liver cancer.
Other outcomes
-
Incidence of adverse events for the participants
Time frame: 5 years
Incidence of ascite, hepatorenal system, hepatic encephalopathy, gastrointestinal bleeding, etc. for all the participants.
Study contacts
Contact information is provided by the study sponsor or research team.
Sponsors and collaborators
Lead sponsor
Sun Yat-sen University
Other
Registry information
Official study title
Research on Risk Assessment and Intervention of HBV-Related Liver Cancer Based on Multimodal Data Fusion
Important dates
- Study start
- 2025
- Primary completion
- 2032
- Study completion
- 2032
- First posted
- Sep 8, 2025
- Registry last updated
- Sep 8, 2025
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Recruiting
Analysis of Methylomic Features and Prognostic Risk Prediction in Patients With Hepatitis B-related Acute-on-chronic Liver Failure
NCT07275554
Blood-Borne Infections, Communicable Diseases
Jinan, Shandong, China
View Trial Details
Not Yet Recruiting
A Study on Peginterferon Alfa-2b Combined With NAs in Compensated HBV Cirrhosis
NCT07183293
HBV-related Liver Cirrhosis
Xiamen, China
View Trial Details